ImmuCell (NASDAQ:ICCC) Shares Pass Above Two Hundred Day Moving Average of $5.01

ImmuCell Co. (NASDAQ:ICCC)’s stock price crossed above its 200-day moving average during trading on Monday . The stock has a 200-day moving average of $5.01 and traded as high as $5.20. ImmuCell shares last traded at $5.10, with a volume of 9,991 shares traded.

ImmuCell Stock Down 0.8 %

The firm has a market capitalization of $39.53 million, a PE ratio of -6.80 and a beta of 0.59. The company has a debt-to-equity ratio of 0.42, a quick ratio of 0.87 and a current ratio of 2.73. The firm’s 50-day moving average is $5.16 and its 200 day moving average is $5.01.

ImmuCell (NASDAQ:ICCC) last released its quarterly earnings results on Tuesday, February 27th. The biotechnology company reported ($0.15) earnings per share for the quarter. The company had revenue of $5.10 million during the quarter. ImmuCell had a negative return on equity of 21.79% and a negative net margin of 33.05%.

Hedge Funds Weigh In On ImmuCell

An institutional investor recently bought a new position in ImmuCell stock. Mission Wealth Management LP acquired a new position in shares of ImmuCell Co. (NASDAQ:ICCC) during the 3rd quarter, according to its most recent filing with the SEC. The institutional investor acquired 10,000 shares of the biotechnology company’s stock, valued at approximately $53,000. Mission Wealth Management LP owned 0.13% of ImmuCell at the end of the most recent reporting period. 13.47% of the stock is currently owned by hedge funds and other institutional investors.

About ImmuCell

ImmuCell Corporation, an animal health company, develops, manufactures, and sells products that enhance the health and productivity of dairy and beef cattle in the United States and internationally. The company operates through two segments, Scours and Mastitis. It offers First Defense, an orally delivered scours preventive product for calves with claims against E.